IDEAYA Biosciences Files 8-K on 'Other Event'; No New Material Info

TL;DR

**IDEAYA Biosciences filed a routine 8-K, no major news for IDYA investors.**

AI Summary

IDEAYA Biosciences, Inc. filed an 8-K on January 12, 2024, to report an 'Other Event.' This filing primarily serves to update administrative details, such as confirming its status as a registrant on The Nasdaq Global Select Market under the trading symbol IDYA. For investors, this filing is largely procedural and does not contain new financial or operational information that would directly impact the stock's valuation, indicating a stable, albeit uneventful, corporate status.

Why It Matters

This filing is largely administrative, confirming IDEAYA Biosciences' registration on Nasdaq and its trading symbol IDYA, without disclosing new material financial or operational information.

Risk Assessment

Risk Level: low — The filing is administrative and does not introduce new risks or significant changes to the company's operations or financial standing.

Analyst Insight

Smart investors would note this filing is purely administrative and contains no new material information, thus it should not influence investment decisions or stock price expectations.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Global Select Market (company) — the exchange where IDEAYA Biosciences' common stock is registered
• IDYA (company) — the trading symbol for IDEAYA Biosciences' common stock
• January 12, 2024 (date) — the date of the earliest event reported in the 8-K
• 001-38915 (dollar_amount) — Commission File Number
• 47-4268251 (dollar_amount) — IRS Employer Identification Number
• 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (company) — Address of principal executive offices
• (650) 443-6209 (dollar_amount) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
• $250.0 million — aving aggregate gross proceeds of up to $250.0 million through Jefferies as sales agent. On
• $57.0 million — for aggregate estimated net proceeds of $57.0 million at a weighted average sales price of ap
• $37.60 — ed average sales price of approximately $37.60 per share under the at-the-market offer

Filing Documents

• idya-20240112.htm (8-K) — 37KB
• 0000950170-24-004395.txt ( ) — 152KB
• idya-20240112.xsd (EX-101.SCH) — 28KB
• idya-20240112_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On June 26, 2023, IDEAYA Biosciences, Inc. (the “Company”) filed a Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a “well-known seasoned issuer”, as defined in Rule 405 under the Securities Act. On June 26, 2023, the Company also entered into an Open Market Sales Agreement, or June 2023 Sales Agreement, with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share, having aggregate gross proceeds of up to $250.0 million through Jefferies as sales agent. On January 12, 2024, the Company sold an aggregate of 1,561,735 shares for aggregate estimated net proceeds of $57.0 million at a weighted average sales price of approximately $37.60 per share under the at-the-market offering pursuant to the June 2023 Sales Agreement. As of January 15, 2024, no amount of common stock remained available to be sold under the at-the-market facility associated with the June 2023 Sales Agreement.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: January 16, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR